Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tenofovir DF to Prevent HBV Mother-to-Child Transmission
NCT02039362Phase 4Completed
- Sponsor
- Hôpital Lariboisière
- Start
- Jul 2012
- Primary completion
- Jan 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of tenofovir disoproxil fumarate in hepatitis B (HBV), sponsored by Hôpital Lariboisière. Primary endpoint: Rate of chronically infected (positive HBs Ag) children at 9 months. Started Jul 2012; status: completed.
02
Drugs
tenofovir disoproxil fumarate
03
Conditions
hepatitis B (HBV)
Beyond the preview
Go deeper on NCT02039362.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02039362.